- Home
- STG vs STTK Comparison
STG vs STTK Comparison
Compare STG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- STTK
- Stock Information
- Founded
- STG 2003
- STTK 2016
- Country
- STG China
- STTK United States
- Employees
- STG N/A
- STTK N/A
- Industry
- STG Other Consumer Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- STTK Health Care
- Exchange
- STG Nasdaq
- STTK Nasdaq
- Market Cap
- STG 112.4M
- STTK 112.6M
- IPO Year
- STG 2018
- STTK 2020
- Fundamental
- Price
- STG $5.66
- STTK $2.01
- Analyst Decision
- STG
- STTK Hold
- Analyst Count
- STG 0
- STTK 5
- Target Price
- STG N/A
- STTK $3.00
- AVG Volume (30 Days)
- STG 2.6K
- STTK 198.9K
- Earning Date
- STG 11-20-2025
- STTK 11-06-2025
- Dividend Yield
- STG N/A
- STTK N/A
- EPS Growth
- STG N/A
- STTK N/A
- EPS
- STG 3.59
- STTK N/A
- Revenue
- STG $279,374,215.00
- STTK $1,000,000.00
- Revenue This Year
- STG N/A
- STTK N/A
- Revenue Next Year
- STG N/A
- STTK N/A
- P/E Ratio
- STG $1.57
- STTK N/A
- Revenue Growth
- STG N/A
- STTK N/A
- 52 Week Low
- STG $4.28
- STTK $0.69
- 52 Week High
- STG $15.00
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- STG 25.52
- STTK 50.71
- Support Level
- STG $6.20
- STTK $1.86
- Resistance Level
- STG $6.98
- STTK $2.08
- Average True Range (ATR)
- STG 0.17
- STTK 0.14
- MACD
- STG -0.07
- STTK -0.00
- Stochastic Oscillator
- STG 13.07
- STTK 65.91
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.